MDGL MADRIGAL PHARMACEUTICALS, INC. Insider Trading

CMO David Soergel sells 1,042 MDGL shares at $495.74 via pre-arranged 10b5-1 plan; stock at $481.23, down -6.3% in 30 days.

David Soergel sold 1,042 shares for $516,561.08 under a 10b5-1 trading plan adopted on 2026-03-02, reducing his holdings from 11,075 shares to 10,033 shares. The transaction was executed at $495.74, while the current price stands at $481.23, representing a -21.8% decline from the 52-week high of $615.00. The stock has declined -6.3% over the past 30 days despite posting +13.0% gains over 90 days. Madrigal's fundamentals show the company posted net income of $-94,391,000.00 on latest quarter revenue of $311,337,000.00, with full-year net income negative; however, annual revenue growth reached +432.0%. As a scheduled transaction under a pre-arranged plan, this sale carries no timing signal regarding executive conviction.

Director Richard S Levy sells 5,682 shares at $515.44 avg ($2.9M) at MDGL; 10b5-1 plan

Richard S Levy, a director at Madrigal Pharmaceuticals, executed 12 separate sales totaling 5,682 shares for $2,928,716.43 on 2026-05-22 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-20, reducing his holdings by -20.5% vs pre-transaction holdings. The company is unprofitable (full-year net income was negative) while showing explosive revenue growth of +432.0% year-over-year, creating valuation tension. Across his cross-ticker track record, Levy's prior 19 sells averaged +8.3% returns over 30 days post-execution, though his same-ticker history at MDGL (5 prior sells in November 2025) showed mixed 30-day outcomes (ranging 7.8%–10.8%) followed by consistent 90-day declines. The scheduled nature of this sale under 10b5-1 removes discretionary timing as a signal of conviction or concern.